Free Trial

Harrow Q1 2023 Earnings Report

Harrow logo
$26.21 -1.66 (-5.96%)
As of 03/28/2025 04:00 PM Eastern

Harrow EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Harrow Revenue Results

Actual Revenue
$26.10 million
Expected Revenue
$25.89 million
Beat/Miss
Beat by +$210.00 thousand
YoY Revenue Growth
N/A

Harrow Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Harrow Earnings Headlines

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call
Why Buffett and 100 members of Congress are Piling into this One Investment
While everyone's distracted by the recent stock market rally and Trump's tariffs... There's a much bigger story that's flying under the radar for now: Why are Warren Buffett, Ken Griffin, Roman Abramovich, the Koch Brothers, Carlos Slim and at least 100 members of Congress all going against "conventional wisdom?" And why are they all piling into ONE overlooked corner of the stock market? It's not crypto... gold... or options strategies.
Harrow, Inc. 2024 Q4 - Results - Earnings Call Presentation
HC Wainwright Analysts Boost Earnings Estimates for Harrow
See More Harrow Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Harrow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harrow and other key companies, straight to your email.

About Harrow

Harrow (NASDAQ:HROW) operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

View Harrow Profile

More Earnings Resources from MarketBeat